Publications

Showing 9 of 0 results

• San Antonio Breast Cancer Symposium

  December 2024

  Real-world demographics, clinical characteristics, and treatment patterns among US patients with HER2-negative early breast cancer and germline BRCA mutations since 2021

  Sardesai S, Berrocal-Almanza L, Wang X, et al.

  • Publication summary
  • Publications
  • Breast cancer

• San Antonio Breast Cancer Symposium

  December 2024

  Clinical characteristics and treatment persistence in US patients with HR+/HER2-, node positive early breast cancer treated with abemaciclib: Real-world study from first year after approval

  Hudson K, Gathirua-Mwangi W, Cui Z, et al.

  • Publication summary
  • Publications
  • Breast cancer

• San Antonio Breast Cancer Symposium

  December 2024

  Tolerability of first-line treatment with ribociclib for metastatic breast cancer using two large US data sources

  Sammons S, Sharma P, Abdou Y, et al.

  • Publication summary
  • Publications
  • Metastatic breast cancer
  • Breast cancer

• San Antonio Breast Cancer Symposium

  December 2024

  Comparative overall survival of CDK4/6is plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting

  Rugo H, Layman R, Lynce F, et al.

  • Publication summary
  • Publications
  • Metastatic breast cancer
  • Breast cancer

• ASH Annual Meeting

  November 2024

  A real-world analysis of the relationship between Epstein-Barr Virus positivity and baseline characteristics, treatment patterns and clinical outcomes in diffuse large B-cell lymphoma

  Yilmaz E, Wang W, Wadé N, et al.

  • Publication summary
  • Publications
  • Diffuse large B-Cell lymphoma

• ASH Annual Meeting

  November 2024

  Design and methodological considerations for real-world data-derived progression-free survival in Multiple Myeloma

  Wang J, Hayden J, Yue Y, et al.

  • Publication summary
  • Publications
  • Multiple myeloma

• ASH Annual Meeting

  November 2024

  The impact of structural racism and social determinants of health on fluorescence in situ hybridization testing among patients with multiple myeloma

  Pierre A, Ho G, Mbah O, Wang J, Ryals C;

  • Publication summary
  • Publications

• ASH Annual Meeting

  November 2024

  Real-world characteristics and survival outcomes of patients with Mantle Cell Lymphoma treated with covalent Bruton's tyrosine kinase inhibitors in first-line

  Sawas A, Wade N, Roose J

  • Publication summary
  • Publications

• ASH Annual Meeting

  November 2024

  Real-world outcomes of Acute Myeloid Leukemia patients undergoing treatment with tyrosine kinase inhibitor (TKI) therapy targeting FLT3, IDH1, or IDH2

  Espinoza-Gutarra M, Jarrett B, Wang X, Afghahi A, Bae S;

  • Publication summary
  • Publications